Breaking News

Catalent, Pure MHC in Product Development Pact

November 21, 2013

To develop humanized version of Pure MHC’s RL21A antibody

Catalent Pharma Solutions and Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, have signed a product development agreement under which Catalent will develop a humanized version of Pure MHC’s RL21A antibody and engineer a cell line to express the antibody using its GPEx technology. Catalent will subsequently produce purified monoclonal antibodies to support preclinical development with humanized RL21A for the treatment of cancer. 
 
“We are confident that our partnership with Catalent will result in the development of the enhanced antibodies necessary to help get RL21A into the clinic more quickly,” said Thomas Harlan, chief executive officer of Pure MHC, “Our ultimate goal for this technology is to one day provide cancer patients with a treatment option that is safer and more effective than those available today.”
 
“We are delighted to again demonstrate how GPEx technology, together with Catalent’s development and manufacturing expertise, can support development of novel therapies and enable companies such as Pure MHC to validate their unique target screening methodology,” said Jonathan Arnold, vice president, general manager of Catalent’s Advanced Delivery Technologies business.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent